Skip to main content
. 2023 Jan 4;13:1044678. doi: 10.3389/fimmu.2022.1044678

Figure 1.

Figure 1

The one-way sensitivity analyses of serplulimab plus chemotherapy group and chemotherapy group. PFS, progression-free survival; AEs, adverses events; PD, progressive disease.